Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden muscle loss in Sjögren's syndrome: a new study looks for answers

NCT ID NCT07804719

Knowledge-focused Sponsor: Antalya Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study examines whether women with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth, also experience muscle loss, a condition called sarcopenia. Researchers will measure muscle strength, muscle mass, and physical performance in 120 participants and compare them with healthy controls. The goal is to understand how muscle loss affects daily function and quality of life in these patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diagnostic tests including DEXA scans, hand grip strength measurements, and blood tests for myostatin and follistatin
What this could lead to
If muscle loss is common in Sjögren's syndrome, this could lead to routine screening and targeted therapies to preserve strength and independence.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients, and the tests are only snapshots of muscle health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

120 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

120

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Voluntarily 2. Women over the age of 18 3. Women diagnosed with primary Sjögren's syndrome Exclusion Criteria: 1. Those with cognitive impairment 2. Pregnancy 3. Malignancy 4. Those with other rheumatic diseases 5. Uncontrolled chronic disease(diabetes mellitus, hypertension, hypothyroidism, hyperthyroidism) 6. Those who have difficulty walking on their own 7. Arthritis present in the dominant hand joints 8. Central and peripheral nervous system findings 9. Myositis and mechanical pain 10. Individuals receiving treatment for hyperlipidemia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Primary Sjögren syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sarcopenia Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Primary Sjögren syndrome Sarcopenia

Contacts and locations

Locations

  • Antalya Training and Research Hospital

    Antalya, 07100, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.